Mechanism-based population pharmacokinetic modelling in diabetes: Vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV

British Journal of Clinical Pharmacology

Volumn 73, Issue 3, 2012, Pages 391-401

  Landersdorfer, Cornelia B ^a,b   He, Yan Ling ^c   Jusko, William J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b MONASH UNIVERSITY   (Australia)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

DPP 4 inhibitor; Mechanism based population modelling; Pharmacokinetics; Type 2 diabetes mellitus; Vildagliptin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DRUG METABOLITE; PLACEBO; VILDAGLIPTIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME SUBSTRATE; FEMALE; HUMAN; HYDROLYSIS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADAMANTANE; ADMINISTRATION, ORAL; ADULT; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NITRILES; PYRROLIDINES;

EID: 84863018661     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.04108.x     Document Type: Article

References (22)

1. Kleppinger EL, Helms K. The role of vildagliptin in the management of type 2 diabetes mellitus. Ann Pharmacother 2007; 41: 824-32.
2. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-57.
3. Idris I, Donnelly R. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. Diabetes Obes Metab 2007; 9: 153-65.
4. He YL, Serra D, Wang Y, Campestrini J, Riviere GJ, Deacon CF, Holst JJ, Schwartz S, Nielsen JC, Ligueros-Saylan M. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet 2007; 46: 577-88.
5. Bulitta JB, Holford NHG. Non-compartmental analysis. In: Wiley Encyclopedia of Clinical Trials, eds. D'Agostino RB, Sullivan L, Massaro J. Hoboken: Wiley & Sons, 2008; dx.doi.org/10.1002/9780471462422.eoct340
6. He YL, Sadler BM, Sabo R, Balez S, Wang Y, Campestrini J, Laurent A, Ligueros-Saylan M, Howard D. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet 2007; 46: 787-802.
7. Beal SL, Ludden T, Boeckmann A, Sheiner LB. NONMEM Users Guides. version VI: San Francisco: University of California, 2008.
8. Bauer RJ. S-ADAPT/MCPEM user's guide (version 1.56). Software for Pharmacokinetic, Pharmacodynamic and Population Data Analysis. Berkeley, CA. 2008.
9. Landersdorfer CB, He Y-L, Jusko WL. Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes. Br J Clin Pharmacol 2012; 73: 373-390.
10. Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 1994; 56: 248-52.
11. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 2001; 28: 507-32.
12. He H, Tran P, Yin H, Smith H, Flood D, Kramp R, Filipeck R, Fischer V, Howard D. Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs. Drug Metab Dispos 2009; 37: 545-54.
13. Mager DE. Target-mediated drug disposition and dynamics. Biochem Pharmacol 2006; 72: 1-10.
14. Brandt I, Joossens J, Chen X, Maes MB, Scharpe S, De Meester I, Lambeir AM. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile. Biochem Pharmacol 2005; 70: 134-43.
15. Hughes TE, Mone MD, Russell ME, Weldon SC, Villhauer EB. NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV. Biochemistry 1999; 38: 11597-603.
16. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999; 85: 9-24.
17. He H, Tran P, Yin H, Smith H, Batard Y, Wang L, Einolf H, Gu H, Mangold JB, Fischer V, Howard D. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos 2009; 37: 536-44.
18. Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, Mangold BL, Russell ME, Hughes TE. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003; 46: 2774-89.
19. Retlich S, Duval V, Graefe-Mody U, Jaehde U, Staab A. Impact of target-mediated drug disposition on linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients. J Clin Pharmacol 2010; 50: 873-85.
20. Jonsson EN, Wade JR, Karlsson MO. Nonlinearity detection: advantages of nonlinear mixed-effects modeling. AAPS PharmSci 2000; 2: E32.
21. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001; 28: 481-504.
22. Bauer RJ, Guzy S, Ng C. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples. AAPS J 2007; 9: E60-83.